In a phase 1/2 study of Japanese patients with CD30‐positive Hodgkin lymphoma or systemic anaplastic large cell lymphoma, the safety profile of brentuximab vedotin was similar for US and Japanese patients, and no remarkable ethnic differences in PK were found.34 This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.